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Abstract
Background: Malignant peripheral nerve sheath tumor (MPNST) is biologically an aggressive tumor for which the treatment
of choice is the surgery. We reviewed the clinical profile, diagnostic methods, treatment patterns, and outcome of twenty-four
MPNST patients in this study.
Patients and methods: A retrospective analysis of 24 MPNST patients, treated from 1994 to 2002, in the department of
Surgical Oncology at All India Institute of Medical Sciences, New Delhi, was done. A combination of gross, histopathological and
immunohistochemical findings, and proliferation markers (MIB1) were considered for diagnosis and grade of the MPNST.
Survival analysis was done by the Kaplan-Meier method and differences were evaluated with the log-rank test. Multivariate
analysis was carried out by using Cox's proportional hazards model by using SPSS (Version 9, Chicago, Illinois) software.
Results: MPNST constituted 12% of all soft tissue sarcomas, where 21% (5/24) of patients had associated Von Recklinghausen's
disease (VRHD). A higher incidence of male preponderance and multifocal MPNST were noted in the present series. At a mean
follow-up of 38 months, 13 (54 %) patients had relapse of disease and 5-year over all and disease free survival were 58% and
35% respectively. In univariate analysis, sex (p = 0.05), tumor depth (p < 0.03), and cellular differentiation (p < 0.002) were shown
to be adverse prognostic factors for disease free survival and sex (p = 0.04), cellular differentiation (p < 0.0004), and tumor
grade (p = 0.05) for overall survival. However, in multivariate analysis, cellular differentiation (p < 0.005) and tumor grade (p <
0.01) emerged as independent prognostic factors for both disease free and overall survival, respectively. Postoperative
radiotherapy (RT) has shown a definite role in both disease free and overall survival in this study.
Conclusion: MPNSTs constituted a significant proportion (12%) of soft tissue sarcoma in our medical center. Heterogeneous
differentiation and multifocality of the tumor were few distinct features of MPNST. Sex and cellular differentiation were noticed
as the new adverse prognostic factors and adjuvant radiotherapy has been proved to be a significant treatment tool in the
current series.
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Background
Malignant peripheral nerve sheath tumor (MPNST) is a
rare variety of soft tissue sarcoma of ectomesenchymal ori-
gin [1,2]. World Health organization (WHO) coined the
term MPNST replacing previous heterogeneous and often
confusing terminology, such as malignant schwannoma,
malignant neurilemmoma, and neurofibrosarcoma, for
tumors of neurogenic origin and similar biological behav-
ior [3,4]. These tumors often create diagnostic problems
because of their cellular origin and histopathological sim-
ilarities with other spindle cell sarcomas like monophasic
synovial sarcoma, leiomyosarcoma and fibrosarcoma [5].
They arise from a major or minor peripheral nerve
branches [6] or sheath of peripheral nerve fibers [7,8].
These tumors may arise spontaneously in adult patients,
although 5% to 42% of MPNST have an association with
multiple neurofibromatosis Type-I [9-12]. Thus, a combi-
nation of gross, histopathological, and immunohisto-
chemical studies are used for diagnosing these tumors.
Another interesting clinical feature of this tumor is multi-
focality and development of second primary tumors of
same histology [5]. Surgery is the main stay of treatment
of this tumor though they are biologically aggressive in
nature [5,12,13]. In this article, we reviewed the case
records of the patients with malignant peripheral nerve
sheath tumors to investigate their clinico-pathological
features, treatment outcome, survival, and prognostic fac-
tors.
Patients and methods
A retrospective analysis of MPNST patients treated in Jan-
uary 1994 to December 2002 in the Surgical Oncology
unit at All India Institute of Medical Sciences, New Delhi
was performed. The source of the data was a soft tissue sar-
coma database. Twenty-four out of 200 soft tissue sar-
coma patients had MPNST. The clinical details, including
the presence or absence of VRHD [14], the histopathol-
ogy, treatment details, and follow-up were analyzed. Pre-
treatment evaluation included core needle biopsy or
incision and/or excision biopsy for the tissue diagnosis.
Extent and stage of the disease was evaluated by the con-
trast enhanced computed tomography (CT) or magnetic
resonance imaging (MRI). Patients with small (<5 cm)
and subcutaneously located tumors underwent no imag-
ing. All patients underwent surgical excision as the pri-
mary therapy and histopathological examination and
immunohistochemical staining confirmed the final diag-
nosis. Adjuvant radiotherapy and chemotherapy was
decided on the basis of the size (>5 cm), depth (deep
seated), grade (high), and recurrence of the tumor. After
completion of therapy all patients were followed-up every
3 monthly on regular basis. Survival was calculated from
the date of diagnosis to the date of last follow-up or death.
The details of local and systemic recurrences and second
primaries were also analyzed. Development of a new sar-
coma of same histology in a different anatomical area was
taken as second primary or multifocal MPNST.
Survival analysis was done by the Kaplan-Meier method
and differences were evaluated with the log-rank test. Mul-
tivariate analysis was carried out by using Cox's propor-
tional hazards model.
Results
MPNST constituted 12% (24/200) of all soft tissue sarco-
mas. Out of 24 patients, 19 were male and 5 were female
(M:F = 3.8:1). The age ranged from 16 to 81 years, with
median age of 40 years. Five out of 24 (21 %) patients had
an associated Von Reckling Hausen's disease. Three
patients had plexiform variety among five patients with
multiple neurofibromatosis. The commonest presenting
symptom was a "mass" (96%) followed by pain (71%).
Only one patient had neurological deficit. Extremities
were the commonest site involved (15/24), followed by
chest wall, trunk, pelvis, and head and neck (Table 1). CT
scan was performed in 6, MRI in 9, and both CT and MRI
scan were performed in 3 patients. Out of 24 patients, 22
(92%) were deep seated and two (8%) were superficial
tumors. Only in eight cases the neural origin of tumors
could be identified intra-operatively (4 in lower limb and
3 in upper limb and one in pelvis), while in the rest, it was
not possible to specifically identify the nerve of origin.
Pathology
The following criteria were used for the histological diag-
nosis of MPNST – a) gross fusiform tumors in relation to
nerves, b) microscopic features of spindle cell with fascic-
ular pattern and varying degrees of mitosis, necrosis and
tumor calcification, c) presence of associated benign neu-
rofibroma or schwannanian cells, and d) positive immu-
nohistochemical staining for S-100 protein, neuron
specific enolase (NSE) and others like actin, cytokeratin
(CK), smooth muscle actins (SMA), desmin, and vimentin
to differentiate from other spindle cell sarcomas. The
tumors were classified as low and high grade on the basis
of their cellular differentiation, mitotic count, tumor
necrosis [15,16] and expression of MIB-1 proliferation
marker [17,18]. Tumor necrosis was evaluated with scor-
ing as 0, 1, and 2, depending on the percentage of necrosis
as 0%, <50%, and >50% presence, respectively. Mitosis
Table 1: Anatomical site distribution of the MPNST.
Site of Tumor Patients (Percentage)
Head and neck 01 (04%)
Chest wall & trunk 06 (25%)
Extremity 15 (63%)
Upper limb 07 (29.2%)
Lower limb 08 (33.8%)
Pelvis 02 (08%)World Journal of Surgical Oncology 2006, 4:55 http://www.wjso.com/content/4/1/55
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rate is also evaluated like wise as 0, 1, and 2, depending
on numbers as <5, 5–10, and >10 per 10 hyper power
field (HPF), respectively. More than 5 mitotic rates per 10
HPF have been considered as high grade tumor as single
mitotic figure may be significant in a tumor with hypercel-
lularity and nuclear atypia [13]. The significance of the
mitoses depends on the prognostic value of increased cell
proliferation. Tumor necrosis scoring was 0 in 14 patients,
1 in 6 and 2 in 4 patients, respectively, while mitotic rate
was 0 in 4, 1 in 8, and 2 in 12 patients, respectively. A >5%
cellular staining of MIB-1 proliferation marker has been
considered as high grade tumors [17,18]. The MIB-1 pro-
liferation marker has been done in twenty cases, where
>5% staining of cells shown a correlation with the high-
grade tumors, while <5% had shown low grade MPNST.
Preoperative tissue diagnosis of malignant nerve sheath
tumor could be made in 15 (62.5%) patients on biopsy
specimens and the remaining were diagnosed as unclassi-
fied malignant mesenchymal tumors. In the final histopa-
thology, all patients were diagnosed as malignant
peripheral nerve sheath tumor. S-100 immunohistochem-
ical stains were used in twenty cases, of these, fifteen cases
(63%) showed strong focal positivity. Other cases were
supported by exclusion method of other soft tissue sarco-
mas by various other immunohistochemical stains. Fif-
teen patients (62.5%) were categorized as having high-
grade and the remaining 9 (37.5%) as low-grade MPNST,
on the basis of above pathological parameters. A peculiar
proliferation of tumor in the sub-endothelial zones of ves-
sels with neoplastic cells herniation into vessel lumen and
proliferation of small vessels in the walls of large vessels
have been noticed in our series, which are very character-
istic features to designate the tumor as MPNST. In our
study, five patients (21%) have shown divergent differen-
tiation of MPNST with heterotrophic such as rhabdoid,
chondroid, myoid, epitheloid and osteoid elements in
each case, respectively. We encountered some rare patho-
logical findings, such as skeletal muscle entrapment and
squamous differentiation, in our series. Size of the tumor
ranged from 4 to 24 cm in greatest diameter (mean 10.83
cm), where twenty-two had more than 5 cm size and 8
had more than 10 cm tumor. Two patients had positive
tumor resection margin after surgery.
Treatment
Curative surgery was performed in all 24 cases in the form
of wide local excision in 17 cases, amputation or disartic-
ulation in 5 cases and two patients had pelvic exenteration
for large pelvic MPNST. Among the 15 patients with
extremity MPNST limb salvage surgery was performed in
10, and the remaining 5 had amputations or disarticula-
tion either for primary or recurrent tumor with neuro-vas-
cular encasement and extensive soft tissue with bone
involvement. In the current study, 8 out of 24 patients
required radical surgery and 16 required conservative sur-
gical procedures. The overall limb salvage rate was 67%.
In view of the size (>5 cm), location, and grade, postoper-
ative adjuvant radiotherapy, ranging from 54 to 62 Gy
(median dose 58 Gy), was given to 16 patients. Three
patients in the radical surgery group and 13 in the con-
servative surgery group received postoperative radiother-
apy. One patient with a Head and Neck MPNST, which
was of rhabdoid differentiation (malignant triton tumor),
was treated by commando operation and given adjuvant
postoperative radiotherapy and chemotherapy. Two
patients had disarticulation for their regional recurrence
of the disease, with one of these finally succumbing to sys-
temic relapse. All systemic relapse patients received palli-
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ative chemotherapy, as no patient was suitable for
curative resection.
Survival
During follow-up, 13 (54 %) patients developed relapse
of the disease, including local, systemic, and second pri-
mary sarcomas of same histology (multifocal MPNST).
Both tumor positive resected margin patients developed
systemic relapse of the disease, including one with local
recurrence. Overall 10 patients (around 77% of all recur-
rences) developed systemic relapse, with lung (7 out of 10
= 70%) being the commonest site, while liver, spleen,
spine, and orbit were other systemic sites noted for rest of
the cases. Eighty percent of systemic relapses (8 out of 10)
occurred within two years of their treatment. The 5-year
overall and disease free survivals were 58% and 38%,
respectively, with median disease free period was 17
months (Figure 1, 2), where as median survival period
was 32 months. Ten out of 24 patients (41%) died due to
disease, one patient with multiple neurofibromatosis died
at the age of 87 not due to disease and the remaining were
alive and disease free. Patients who had not received post
operative RT had no 5 year disease free survival, while
42% patients who received RT were disease free after 5
years in the current series in Kaplan Meier survival curve.
Similarly, 65% patients received postoperative RT had 5
year overall survival versus only 38% patients not received
RT. (Figure 3, 4).
Prognostic factors
Sex, tumor depth, VRHD, tumor necrosis, mitotic rate, cel-
lular differentiation, and tumor grade, heterogeneous dif-
ferentiation of tumor, radiotherapy treatment, and relapse
of the disease were studied for prognostic factors.
In univariate analysis, sex, tumor depth, and cellular dif-
ferentiation were shown to be adverse prognostic factors
for the disease free survival, while sex, cellular differentia-
tion (Figure 5, 6), tumor grade, and relapse of the disease
were shown to be negative prognostic factors for overall
survival (Table 2). In multivariate analysis, cellular differ-
entiation and tumor grade emerged as independent
adverse prognostic factors for  disease free and overall sur-
vival respectively (Table 3). VRHD association, tumor
necrosis, and mitosis rate did not have any impact on sur-
vival.
Discussion
MPNST is a very rare tumor, with an incidence of 1 per
1,00,000 population and whichconstitutes between 3 to
10% of all soft tissue sarcomas. Hence, this entity is often
managed as a sub-category of soft tissue sarcomas [1,2]. In
contrast, in our series, MPNST constituted 12% (24/200)
of all soft tissue sarcomas, with MPNST representing the
second most common variety of soft tissue sarcoma seen.
The most significant contributions in understanding the
clinical and pathological features of MPNST were studied
by Mayo clinic investigators [6,16,19]. A combination of
gross and microscopic findings along with immunohisto-
chemical studies is commonly used to diagnose a case of
MPNST [5]. In most instances, the tumors display fascicles
of spindle cells woven into herringbone pattern with var-
ying degrees of mitosis and necrosis. However, it is not
always possible to demonstrate the origin from a nerve,
especially when it arises from a small peripheral branch.
This point was exemplified in a series by Nambisan et al.,
in which nerves could not be identified in 61% of cases of
MPNST [12] and in the series Bilge et al., in which nerve
origin could be identified only in 45–56% cases [20]. Still,
there are several other distinct features, such as prolifera-
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tion of tumor in the sub-endothelial zones of vessels with
nepotistic cells herniation into vessel lumen and prolifer-
ation of small vessels in the walls of the large vessels,
which are very characteristic features of MPNST [21], as
noticed in our series.
In our series, grade of the tumor emerged as the significant
prognostic factor for overall survival. Likewise, cellular
differentiation emerged as a significant prognostic factor
for disease free survival in both univariate and multivari-
ate analysis. However, other pathological findings, such as
mitosis and tumor necrosis, had no impact on survival in
our series. In our series, the index of increasing prolifera-
tion, MIB-1, was clearly correlated with grade of the tumor
and simultaneously with prognosis of the disease. Ducat-
man et al. [5] reported that tumor grade and mitotic count
were of no prognostic utility, while Enzinger et al. [21]
noticed that grade of the tumor, necrosis, vascular inva-
sion, and presence of mitosis have significant influence
on survival of the patient. We have 21% of patients who
have heterotrophic pathological features of the tumor;
however, such divergent differentiation did not affect the
survival (Table 2). In contrast, Ramanathan et al. [22] and
Scheithauer et al. [23] have reported the divergent differ-
entiation as a significant adverse prognostic marker for
MPNST in their series.
These tumors occur with equal frequency in males and
females and some series have shown a female preponder-
ance [6,7]. However, we found a significant male prepon-
derance (80 %) in the current study and this significantly
influenced the disease free (p = 0.05), as well as overall
survival (p = 0.04). But it is very difficult to draw any con-
clusion about sex as significant prognostic factor due to
small series and it may be due to referral bias. As far as the
site distribution was concerned. The majority had involve-
ment of the extremities, although tumors were also seen
in unusual sites, such as the pelvic retroperitoneum and
Table 3: Prognostic factors affecting disease free survival and overall survival in multivariate analysis.
Variables Chi Square 95% C.I. Hazard Ratio P Value
DFS
1. Cellular differentiation 10.51 4.20 – 463.30 0.3101 0.005*
OS
1. Tumor Grade 6.08 1.41 – 3.07 0.2741 0.01*
C.I. = Confidence Interval, DFS = Disease free survival, OS = Overall survival, *: Statistically Significant.
Table 2: Prognostic factors affecting disease free survival and overall survival in univariate analysis.
Variables Chi Square 95% C.I. P Value
DFS
1. Sex 3.84 0.92 – 12.93 0.05*
2. Tumor depth 4.23 5.3 – 9.4 <0.03*
3. VRHD 0.28 0.28 – 3.9 0.59
4. Tumour Necrosis 0.56 0.2 – 10.4 <0.76
5. Tumor mitosis 0.027 0.22–3.53 >0.86
6. Cellular differentiation 11.95 2.01 – 111.75 <0.002*
7. Tumor grade 1.69 0.14 – 1.51 >0.19
8. Heterogeneous differentiation 1.73 0.14 – 1.48 0.18
9. RT 2.49 0.76 – 8.42 0.11
OS
1. Sex 4.02 0.94 – 13.27 0.04*
2. Tumor depth 1.86 0.4 – 1.18 0.17
3. VRHD 0.15 0.18 – 4.08 >0.37
4. Tumor Necrosis 0.6 0.2–14.2 >0.74
5. Tumor Mitosis 0.012 0.2–4.8 >0.98
6. Cellular differentiation 15.50 2.44 – 334.28 <0.0004*
7. Tumor grade 3.84 0.94 – 4.68 0.05*
8. Heterogeneous differentiation 0.89 0.15 – 1.95 0.34
9. RT 2.66 0.10 – 1.28 >0.10
10. Recurrence 9.49 0.3 – 2.61 <0.002*
C.I. = Confidence Interval, DFS = Disease free survival, OS = Overall survival, VRHD = Von Reckling hausen's disease, RT = Radiotherapy, *: 
Statistically Significant.World Journal of Surgical Oncology 2006, 4:55 http://www.wjso.com/content/4/1/55
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infratemporal fossa. In our series, the site of the tumor
had no impact on survival of the patients (extremity ver-
sus others was p < 0.06).
The association of MPNSTs with VRHD is well known
[7,8,23] and the series reported 5% to 42% neurofibroma-
tosis patients develop sarcomas. In a review of 71 years
experience, Ducatman et al., [5] estimated that the risk of
developing MPNST in VRHD to be 4600 times greater
than the general population. In the current study, 21 % of
patients had clinical features of VRHD, but their associa-
tion did not affect the survival of the patients (Table 2),
which is in contrast to the findings of other authors
[1,5,24]. In fact, the longest surviving patient in our series
was a patient having multiple neurofibromatosis who pre-
sented with 14 malignant transformations of benign neu-
rofibromas over an 8-year period.
Routine preoperative electrophysiological examination is
not integral to the management of MPNST. This is so since
such an examination neither contributes to the diagnosis
nor influences the treatment plan [2]. Imaging is routinely
performed to assess the extent of the disease and plan sur-
gical resection. However, it does not reliably determine
the malignant transformation from neurofibroma to
MPNST [13]. A target lesion in T2MR image is an indica-
tion of low grade while heterogenous lesion due to necro-
sis & hemorrhage and patchy contrast enhancement in
MRI is an indication of malignant MPNST [25,26]. MRI is
the investigation of choice because it can reveal the nerve
of origin and its relationship to adjacent structures [27].
Clinical behavior of the disease with radiological correla-
tion can also guide to plan the treatment. More impor-
tantly, we used contrast enhanced computed tomography
(CECT) for assessment of pulmonary metastasis, where
MRI has limitations, and also for some primary cases,
when MRI was not available initially at our institute.
Radical surgical resection is the treatment of choice in
MPNST. A good three-dimensional clearance is manda-
tory for a successful outcome. Amputations are indicated
only when wide excision is not feasible and in patients
with severely compromised limb function. Routine nodal
dissection is not indicated. However, when a major nerve
is identified, the cut end should be sent for frozen section
to assess the tumor free margin of the resection. MPNSTs
are generally considered chemotherapy and radiotherapy
resistant tumors. However, there are reports of routine
postoperative radiotherapy and even radiotherapy as a
Shows Kaplan Meier projected survival curve indicating the  influence of relapse of the disease on overall survival of the  patients Figure 7
Shows Kaplan Meier projected survival curve indicating the 
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single modality alone for MPNST in literature [28]. In
view of the rarity of this entity and conflicting reports, it is
difficult to define the role of radiation in the management
of MPNSTs. Currently, postoperative radiotherapy is rec-
ommended by oncology consensus group [13] as part of
a uniform treatment policy for MPNSTs, much like other
high grade soft tissue sarcomas [3,9], despite having clear
surgical margins. Basso-Ricci [29] demonstrated 56% dis-
ease free survival using combined surgery and radiation
therapy for MPNST. Although adjuvant radiotherapy has
not been cited as a significant prognostic factor (Table-2)
in the current study, the results demonstrated in Figure 7
and 8 do reveal a trend towards an impact on both disease
free and overall survival. The indication of radiation treat-
ment are biased towards patients having tumors with
poor prognosis (high-grade or recurrent, deep seated, and
bigger size), and thus failing to show the statistically sig-
nificant difference between radiated and non-radiated
patients.
MPNST has the highest recurrence rate of any sarcomas
[30], and adequate initial treatment gives the best chance
of survival [28]. In the current series, recurrence after ini-
tial treatment, whether local or metastatic, has been cited
as a poor prognostic factor for overall survival (P < 0.002,
Figure 7). The most important feature in present study was
the nature of the disease relapse due to which even one
patient could not be surgically salvaged and were treated
with palliative chemotherapy.
Conclusion
MPNST constitutes a significant proportion of soft tissue
sarcoma in our study. A combination of clinical, patho-
logical, and immunohistochemistry helps in diagnosing
these tumors. Proliferation marker (MIB1) can be a good
adjunct to grade and tailor the treatment in MPNST. The
overall treatment approach should be like that of any
other high grade sarcomas. Heterogeneous differentiation
and multifocality of the tumor were few distinct features
of MPNST in our series. Sex and cellular differentiation
emerged as the new adverse prognostic factors for survival
of the patients, where as VHRD association had no impact
on survival in our study. Postoperative radiotherapy has a
definite role in both disease free and overall survival.
Though multimodality therapy, including surgical resec-
tion and adjuvant radiotherapy, is available, the prognosis
remains dismal. Modern clinical studies and the develop-
ment of effective targeted chemotherapy are needed to
gain control of the disease.
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